EUVIMEDEUVIMED entdecken
Open Access

Sodium–glucose cotransporter 2 inhibitor-induced postoperative euglycaemic diabetic ketoacidosis after pancreatectomy

Misha T Armstrong, Max Murray-Ramcharan, James H Flory, William R Jarnagin, Alice C Wei iD

British Journal of Surgery · 2023

DOI: 10.1093/bjs/znad044 ↗

Kurz gefasst

Fachartikel in der Zeitschrift British Journal of Surgery, 2023. Verfasst von Misha T Armstrong und 4 weiteren Autor:innen. Beteiligte Einrichtung: Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA. Hauptthemen laut MEDLINE: Diabetic Ketoacidosis, Diabetes Mellitus, Type 2. Die Arbeit nennt 16 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, National Cancer Institute, NIH.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Diabetes mellitus (DM) is present in up to 15 per cent of patients undergoing surgery1. This is likely an underestimate for patients undergoing pancreatectomy given that new-onset DM or impaired glucose intolerance occurs in up to 80 per cent of patients with pancreatic ductal adenocarcinoma (PDAC)2. Sodium–glucose cotransporter 2 inhibitors (SGLT2i) inhibit the reabsorption of glucose in the proximal tubule leading to glucosuria and are rapidly growing in popularity, with indications for the treatment of diabetes, heart failure, and kidney disease3. Euglycaemic diabetic ketoacidosis (euDKA) is a known complication associated with SGLT2i, with the US Food and Drug Administration (FDA) first releasing a warning about the adverse event in 20154,5. SGLT2i use in the setting of metabolic stress of surgery greatly increases the risk of SGLT2i-induced euDKA6. Multiple case reports have highlighted the risk of euDKA in the perioperative period7–9. However, little is known about the incidence of DKA in patients on SGLT2i post-partial pancreatectomy. The goals of this short report are to describe the experience with patients on SGLT2i in the perioperative period and to highlight the potential dangers of use of this drug class in pancreatectomy. A retrospective review of consecutive patients from January 2015 to June 2021 was performed using prospectively maintained databases. Patients undergoing partial pancreatectomy for all aetiologies on diabetic medications were identified to determine which patients were on a SGLT2i (canagliflozin, dapagliflozin, empagliflozin, or ertugliflozin) in the preoperative period. Sociodemographics, perioperative variables, postoperative complications, and relevant laboratory values, including haemoglobin A1c (HbA1c), glucose, and creatinine were reviewed. Diabetic ketoacidosis (DKA) was defined as pH < 7.35 on venous or arterial blood gas, serum bicarbonate < 18 meq/l, and ketonuria. Institutional Review Board approval was obtained. We identified 27 patients actively taking a SGLT2i. The majority of patients underwent a pancreaticoduodenectomy (52 per cent) or distal pancreatectomy (41 per cent). Surgical pathology demonstrated PDAC in 59 per cent of the patients. HbA1c was documented for 22 patients, with an average baseline of 7.53 per cent. All patients received pasireotide for pancreatic fistula prevention except for one who received octreotide based on institutional standard practices at that time. On average, SGLT2i were stopped 1.7 days prior to surgery. Four of the 27 patients (15 per cent) had a diagnosis of euDKA and three of these required transfer to the ICU for a continuous insulin infusion. All four patients took their last dose of SGLT2i the day prior to surgery (n = 16). Patients were diagnosed between 2 to 4 days after surgery. In all cases, ketones and glucose were present on urinalysis and laboratory abnormalities led to inpatient consults to endocrinology. Pertinent medical history and diagnostic laboratory values are summarized in Tables S1 and S2, respectively. Fifteen per cent of the patients who were taking SGLT2i preoperatively developed euDKA, with three requiring transfer to ICU for further management. The American Association of Clinical Endocrinologists and the American College of Endocrinologists guidelines recommend cessation of SGLT2i 24 h before surgery10. Given the long half-life of SGLT2i, others suggest that 24 h is not long enough10,11. The FDA now recommends cessation 3–4 days prior to surgery11,12. Despite this, on average, patients on SGLT2i at our institution held their medication less than 2 days prior to surgery, and all patients with euDKA stopped their SGLT2i only the day before surgery. In a retrospective review of patients taking SGLT2i undergoing a variety of surgical procedures, the prevalence of euDKA was 0.17 per cent and 1.1 per cent in non-emergent and emergent procedures, respectively12. Although the complete breakdown of procedures was not included, none of the patients with euDKA underwent pancreas resection. A higher rate of DKA was noted in another retrospective review of cardiac surgery patients, with 15.3 per cent of patients on SGLT2i developing DKA postoperatively13. In more complex procedures requiring prolonged fasting and increased postoperative inflammation, the risk of SGLT2i-induced DKA is likely higher. Pancreas surgery presents a unique clinical scenario with increased risk of diabetes in patients with pancreatic cancer and the removal of functional pancreas tissue. The degree of endocrine insufficiency is likely related to the region of pancreas resected and the volume of healthy remnant pancreas14. Supporting this concern, there are case reports of patients developing euDKA post-partial pancreatectomy6,15. Our findings build on this literature and suggest that euDKA post-partial pancreatectomy may be a common adverse event. In addition to taking prophylactic steps, including holding the SGLT2i for 3–4 days prior to surgery, providers should maintain a high index of suspicion for euDKA. Notably, DKA can masquerade as other postoperative complications with patients presenting with symptoms such as abdominal pain, nausea, or tachypnoea, which may lead to unnecessary imaging or surgical intervention16. Further, there is a high incidence of metabolic acidosis in the postoperative period among all surgery patients with an association between SGLT2i and euDKA demonstrated in a retrospective matched cohort study1. As such, close perioperative monitoring in patients taking a SGLT2i is necessary to ensure acidosis is not mistaken for normal postoperative stress response and for timely diagnosis. The most important limitation of this analysis is the small sample size, although it is still, to our knowledge, the largest study of SGLT2i safety in the setting of pancreas surgery and the only study that reports an incidence rate (in contrast to previously published case reports). Further limitations to our approach include the use of electronic medical record data rather than prospective data collection. This could lead to potential misclassification of both medication exposure and the outcome. However, active medications are routinely reviewed on the day of surgery and medication reconciliation records, preoperative histories, and endocrinology consult notes were reviewed to ensure consistency in medications reported. euDKA was potentially underestimated in our cohort as we only identified patients who required higher levels of care during their initial surgical admission. Findings might not be generalizable to other institutional settings, for example those where somatostatin analogues are not given postoperatively. Misha Armstrong (Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Writing—original draft, Writing—review & editing), Max Murray-Ramcharan (Conceptualization, Data curation, Methodology, Writing—original draft), James Flory (Conceptualization, Methodology, Supervision, Writing—review & editing), and Alice Wei (Conceptualization, Methodology, Supervision, Writing—review & editing) This work was supported by National Cancer Institute award P30 CA008748. The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication. The authors thank the following members of the Memorial Sloan Kettering Hepatopancreatobiliary Service for their support: Drs. Vinod Balachandran, Michael D'Angelica, Jeffrey Drebin, T. Peter Kingham, and Kevin Soares. The authors declare that they have no conflicts of interest to disclose other than the funding sources acknowledged above. Supplementary material is available at BJS online. The data to support the findings described in this report are available from the corresponding author upon reasonable request.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetic KetoacidosisDiabetes Mellitus, Type 2HumansPancreatectomyGlucoseSodium

Substanzen

GlucoseSodium

Autor:innen und Institutionen

  • Hepatopancreatobiliary Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA.
  • Department of General Surgery, Harlem Hospital Center, Harlem, New York, USA.
  • Endocrinology Service, Department of Subspecialty Medicine, Memorial Sloan Kettering Cancer Center, New York, New York, USA.

ORCID-Profile: Alice C Wei

Förderung

  • NCI NIH HHS
  • National Cancer Institute
  • NIH

Zitieren

APA

Armstrong, M. T., Murray-Ramcharan, M., Flory, J. H., Jarnagin, W. R., & Wei, A. C. (2023). Sodium–glucose cotransporter 2 inhibitor-induced postoperative euglycaemic diabetic ketoacidosis after pancreatectomy. British Journal of Surgery. https://doi.org/10.1093/bjs/znad044

Vancouver

Armstrong MT, Murray-Ramcharan M, Flory JH, Jarnagin WR, Wei AC. Sodium–glucose cotransporter 2 inhibitor-induced postoperative euglycaemic diabetic ketoacidosis after pancreatectomy. British Journal of Surgery. 2023. doi:10.1093/bjs/znad044

BibTeX
@article{Armstrong2023,
  author = {Armstrong, Misha T and Murray-Ramcharan, Max and Flory, James H and Jarnagin, William R and Wei, Alice C},
  title = {Sodium–glucose cotransporter 2 inhibitor-induced postoperative euglycaemic diabetic ketoacidosis after pancreatectomy},
  journal = {British Journal of Surgery},
  year = {2023},
  doi = {10.1093/bjs/znad044}
}
Kostenlos starten →